European product revenues threatened by IP policy amendment

As European inventors at universities and small biotechs struggle with new patent policies that will make it harder to protect life science inventions, at the other end of the spectrum, large commercialization-stage biopharmas in Europe are facing their own IP issues, including a policy change that will cut into revenues from patent-protected products.

By the end of the year, the European Patent Office plans to enact a proposal to streamline review of patent applications that could unintentionally harm life science inventors at small biotechs and universities (see “European Patent Proposal Presents Paradoxical Risk for Academics and Biotechs”). ...